Jeffrey Hackman

Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD.

Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada.

Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Part of Takeda Pharmaceutical Co., Ltd., Baxalta US, Inc. engages in the research, development, and manufacture of biopharmaceutical products. The company is based in Deerfield, IL.

Part of Essetifin SpA, Sigma-tau Healthscience USA, Inc. provides health solutions that focus on mitochondrial functioning. Sigma-tau Healthscience USA is based in Gaithersburg, MD. Mitochondria are the energy factories of cells, and healthy mitochondria contribute to various health benefits. Sigma-tau Healthscience USA's Mitocarn™ provides healthy mitochondrial functioning in three ways: by providing energy to the body, supporting mitochondrial function, and strengthening core cellular functions. The company offers four targeted L-carnitine solutions, including Mitocarn™ Heart, which provides extra energy to heart cells during the metabolic process and helps increase blood flow to the heart and muscles.

Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million.